ClinicalTrials.gg
Active, not recruitingNCT02993523Viale-aUpdated Jun 11, 2026Results posted

A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Participants With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy

A Phase 3 interventional study of Azacitidine and Venetoclax in Acute Myeloid Leukemia (AML), sponsored by AbbVie. Active, not recruiting at 172 sites in 29 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-11.

Sponsored by AbbVie · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
443
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 202 studies testing venetoclax in Leukemia, Myeloid, Acute — 116 open to participants now, 144 under way, 21 of them phase 3. venetoclax · Leukemia, Myeloid, Acute.

Enrollment
10th of 202
443 · median 57
Started
2017
with 6 others
Phase 3
16 of 202
7 open now
Primary completion
2021-12
later than 0 of 143 live
Registered
9th of 202
by date
Lead sponsor
15 of 202
AbbVie

Among the 202 studies testing venetoclax in Leukemia, Myeloid, Acute, this one is the 10th largest by enrollment, is one of 7 that started in 2017, is one of 16 in phase 3, reaches primary completion later than 0 of the 143 other live ones, and was the 9th registered.

Leukemia, Myeloid, Acute

3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 817 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

116 of the 202 studies testing venetoclax in Leukemia, Myeloid, Acute are open now, in 12 countries. Recruiting first, the newest first:

111 more — sign in →

By country, each count listing its studies:

All 116 open studies →

About venetoclax

venetoclax: first FDA approval 2016 (VENCLEXTA), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 363 (58%) set no upper age limit and 222 (36%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 202 studies testing venetoclax in Leukemia, Myeloid, Acute, or all of them as a file.
02

Study summary

Acute Myeloid Leukaemia (AML) is an aggressive and rare cancer of myeloid cells (a white blood cell responsible for fighting infections). Successful treatment of AML is dependent on what subtype of AML the participant has, and the age of the participant when diagnosed.

Venetoclax is an experimental drug that kills cancer cells by blocking a protein (part of a cell) that allows cancer cells to stay alive. This study is designed to see if adding venetoclax to azacitidine works better than azacitidine on its own.

This is a Phase 3, randomized, double-blind (treatment is unknown to participants and doctors), placebo controlled study in patients with AML who are >= 18 or more years old and have not been treated before. Participants who take part in this study should not be suitable for standard induction therapy (usual starting treatment). AbbVie is funding this study which will take place at approximately 180 hospitals globally and enroll approximately 400 participants.

In this study, 2/3 of participants will receive venetoclax every day with azacitidine and the remaining 1/3 will receive placebo (dummy) tablets with azacitidine.

Participants will continue to have study visits and receive treatment for as long as they are having a clinical benefit. The effect of the treatment on AML will be checked by taking blood, bone marrow, scans, measuring side effects and by completing health questionnaires. Blood and bone marrow tests will be completed to see why some people respond better than others. Additional blood tests will be completed for genetic factors and to see how long the drug remains in the body.

03

Conditions studied

  • Acute Myeloid Leukemia (AML)

Keywords

  • Acute Myeloid Leukemia
  • Venetoclax
  • Treatment Naïve
  • Azacitidine
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must have confirmation of Acute Myeloid Leukemia (AML) by World Health Organization (WHO) criteria, previously untreated and be ineligible for treatment with a standard cytarabine and anthracycline induction regimen due age or comorbidities.
  • Participant must be >= 18 years of age.
  • Participant must have a projected of at least 12 weeks.
  • Participant must be considered ineligible for induction therapy defined by the following:

    a. >= 75 years of age; or b. >= 18 to 74 years of age with at least one of the following comorbidities: i. (ECOG) Performance Status of 2 or 3; ii. Cardiac history of Congestive Heart Failure (CHF) requiring treatment or \<= 50% or chronic stable angina; iii. Diffusing capacity of the Lung for Carbon Monoxide (DLCO) \<= 65% or (FEV1) \<= 65%; iv. >= 30 mL/min to \< 45 ml/min; v. Moderate hepatic impairment with total > 1.5 to \<= 3.0 × (ULN); vi. Any other comorbidity that the physician judges to be incompatible with intensive chemotherapy must be reviewed and approved by the AbbVie Therapeutic Medical Director during screening and before study enrollment.

  • Participant must have an ECOG Performance status:

    1. 0 to 2 for Participants >= 75 years of age or
    2. 0 to 3 for Participants >= 18 to 74 years of age.
  • Participant must have adequate renal function as demonstrated by a creatinine >= 30 mL/min; calculated by the Cockcroft Gault formula or measured by 24 hours urine collection.
  • Participant must have adequate liver function as demonstrated by:

    1. (AST) \<= 3.0 x ULN*
    2. alanine aminotransferase (ALT) \<= 3.0 x ULN*
    3. bilirubin \<= 1.5 x ULN* * Unless considered to be due to leukemic organ involvement

    i. Participants who are \< 75 years of age may have a bilirubin of \<= 3.0 x ULN

  • Female participants must be either defined as:

    1. Age > 55 years with no menses for 12 or more months without an alternative medical cause.
    2. Age ≤ 55 years with no menses for 12 or more months without an alternative medical cause AND an follicle stimulating hormone (FSH) level >40 international units per liter (IU/L); or
    3. Permanently surgical sterile (bilateral oophorectomy, bilateral salpingectomy or hysterectomy); or
    4. Women of (WOCBP) practicing at least one protocol specified method of , starting at Study Day 1 through at least 90 days after the last dose of study drug.
  • Male participants who are sexually active, must agree, from Study Day 1 through at least 90 days after the last dose of study drug, to practice the protocol specified contraception. Male subjects must agree to refrain from sperm donation from initial study drug administration through at least 90 days after the last dose of study drug.
  • Female participants of childbearing potential must have negative results for pregnancy test performed:

    1. At Screening with a serum sample obtained within 14 days prior to the first study drug administration, and
    2. Prior to dosing with urine sample obtained on Cycle 1 Day 1, if it has been > 7 days since obtaining the serum pregnancy test results.
  • Participant must voluntarily sign and date an , approved by an Independent Ethics Committee (IEC)/Institutional Review Board (IRB), prior to the initiation of any screening or study-specific procedures.

Exclusion criteria

Exclusion Criteria:

  • Participant has received treatment with the following:

    1. A hypomethylating agent, venetoclax and/or chemo therapeutic agent for Myelodysplastic syndrome (MDS).
    2. Chimeric Antigen Receptor (CAR)-T cell therapy.
    3. Experimental therapies for MDS or Acute Myeloid Leukemia (AML).
    4. Current participation in another research or observational study.
  • Participant has history of myeloproliferative neoplasm (MPN) including myelofibrosis, essential thrombocythemia, polycythemia vera, chronic myeloid leukemia (CML) with or without BCR-ABL1 translocation and AML with BCR-ABL1 translocation.
  • Participant has the following:

    a. Favorable risk cytogenetics such as t(8;21), inv(16) or t(16;16) or t(15;17) as per the National Comprehensive Cancer Network (NCCN) Guidelines Version 2, 2016 for Acute Myeloid Leukemia.

  • Participant has acute promyelocytic leukemia
  • Participant has known active central nervous system (CNS) involvement with AML.
  • Participant has known (HIV) infection (due to potential drug-drug interactions between antiretroviral medications and venetoclax) HIV testing will be performed at Screening, only if required per local guidelines or institutional standards.
  • Participant is known to be positive for or C infection [ Ab indicative of a previous or current infection; and/or positive HBs Ag or detected sensitivity on hepatitis B virus (HBV) deoxyribonucleic acid (DNA) polymerase chain reaction (PCR) test for HBc Ab and/or HBs Ab positivity] with the exception of those with an undetectable viral load within 3 months screening. Hepatitis B or C testing is not required.
  • Participant has received strong and/or moderate inducers within 7 days prior to the initiation of study treatment; additional details as described in the protocol.
  • Participant has consumed grapefruit, grapefruit products, Seville oranges (including marmalade containing Seville oranges) or Starfruit within 3 days prior to the initiation of study treatment.
  • Participant has a cardiovascular disability status of Class > 2. Class 2 is defined as cardiac disease in which patients are comfortable at rest but ordinary physical activity results in fatigue, palpitations, dyspnea, or anginal pain.
  • Participant has chronic respiratory disease that requires continuous oxygen, or significant history of renal, neurologic, psychiatric, endocrinologic, metabolic, immunologic, hepatic, cardiovascular disease, any other medical condition or known to any of the study medications including of azacitidine that in the opinion of the investigator would adversely affect his/her participating in this study.
  • Participant has a malabsorption syndrome or other condition that precludes enteral route of administration.
  • Participant exhibits evidence of other uncontrolled systemic infection requiring therapy (viral, bacterial or fungal).
  • Participant has a history of other within 2 years prior to study entry, with the exception of:

    1. Adequately treated in situ carcinoma of the cervix uteri or carcinoma in situ of breast;
    2. Basal cell carcinoma of the skin or localized squamous cell carcinoma of the skin;
    3. Previous malignancy confined and surgically resected (or treated with other modalities) with curative intent; requires discussion with TA MD.
  • Participant has a white blood cell count > 25 × 10\^9/L. (Hydroxyurea or leukapheresis are permitted to meet this criterion.)
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
443 participants (actual)

Study arms

  • Placebo comparator
    Group 1 and Group 2: Placebo + Azacitidine 75 mg/m^2

    Participants enrolled under original protocol and enrolled during or after protocol amendment 1 received venetoclax-matching placebo, orally, every day (QD), from Day 1 to Day 28 of each 28 day cycle along with azacitidine 75 mg/m\^2, subcutaneously (SC) or intravenously (IV), QD for 7 days from Day 1 of each 28-day cycle until documented disease progression, unacceptable toxicity, withdrawal of consent, or other protocol criteria for discontinuation (whichever occurred first).

    Drug: Azacitidine · Drug: Placebo

  • Active comparator
    Group 1 and Group 2: Venetoclax 100 mg/200 mg/400 mg + Azacitidine 75 mg/m^2

    Participants enrolled under original protocol and enrolled during or after protocol amendment 1 received venetoclax 100 mg, once orally, on Day 1 of Cycle 1 followed by venetoclax 200 mg, once orally, on Day 2 of Cycle 1 and venetoclax 400 mg, orally, QD, on Day 3 to Day 28 of each 28 day cycle along with azacitidine 75 mg/m\^2, SC or IV, QD for 7 days from Day 1 of each 28-day cycle until documented disease progression, unacceptable toxicity, withdrawal of consent, or other protocol criteria for discontinuation (whichever occurred first).

    Drug: Azacitidine · Drug: Venetoclax

  • Active comparator
    Open Label China Cohort: Venetoclax 400 mg + Azacitidine 75 mg/m^2

    Participants received venetoclax 400 mg, orally, QD, from Day 1 to Day 28 of each 28 day cycle along with azacitidine 75 mg/m\^2, SC, QD for 7 days from Day 1 of each 28-day cycle until documented disease progression, unacceptable toxicity, withdrawal of consent, or other protocol criteria for discontinuation (whichever occurred first).

    Drug: Azacitidine · Drug: Venetoclax

Interventions

  • Solution for subcutaneous or intravenous administration.

  • Tablet

    Also known as: ABT-199

  • DrugPlacebo

    Matching placebo tablet

06

What researchers measure

Primary outcomes

  1. Overall Survival (OS)

    OS is defined as the number of days from the date of randomization to the date of death. Log rank test was used to compare the OS distribution between two treatment arms. Cox regression was used to report the hazard ratio.

    Time frame: From the study start up to death or alive or lost to follow-up (up to approximately 4.8 years; data cut off date: 1 December 2021)

  2. Percentage of Participants With Complete Remission (CR) and Complete Remission With Incomplete Marrow Recovery (CRi)

    CR and CRi was calculated based on current International Working Group (IWG) criteria. CR is defined as absolute neutrophil count \>10\^3/ microliter (mcL), platelets \>10\^5/mcL, red cell transfusion independence, and bone marrow with \<5% blasts. CRi is defined as bone marrow with less than 5% blasts, and absolute neutrophils of ≤10\^3/mcL or platelets ≤10\^5/mcL. Percentages are rounded off to whole number at the nearest decimal.

    Time frame: From the study start up to death (up to approximately 4.8 years; data cut-off date: 1 December 2021)

Secondary outcomes

  1. Event-free Survival (EFS)

    EFS will be defined as the number of days from randomization to the date of progressive disease, relapse from CR or CRi, treatment failure or death from any cause.

    Time frame: Measured up to 2 years after the last participant is randomized

  2. Global Health Status/Quality of Life (GHS/QoL)

    Improvement in GHS/QoL will be assessed using the Patient Reported Outcomes Measurement Information System (PROMIS) and European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core (EORTC QLQ-C30).

    Time frame: Measured at participant's Day 1 of Cycle 1 (each cycle is 28 days) and at Day 1 of every Cycle thereafter for up to 2 years following the last subject last visit

  3. Percentage of Participants Achieving Composite Complete Remission (CR or CRi)

    This will be calculated based on current International Working Group (IWG) criteria. CR is defined as absolute neutrophil count \> 10\^3/mcL, platelets \> 10\^5/mcL, red cell transfusion independence, and bone marrow with \< 5% blasts. CRi is defined as bone marrow with less than 5% blasts, and absolute neutrophils of \<= 10\^3/mcL or platelets \<= 10\^5/mcL.

    Time frame: Up to 6 months after the first 225 participants are randomized

  4. Complete Remission or Complete Remission With Partial Hematologic Recovery Rate (CR+CRh)

    A response of CRh is defined as Bone marrow with \<5% blasts, peripheral blood neutrophil count \>0.5\*10\^3/mcL and peripheral blood platelet count \>0.5\*10\^5/mcL.

    Time frame: Measured up to 2 years after the last participant is randomized

  5. Post Baseline Transfusion Independence Rate

    Transfusion Independence is defined as a period of 56 days with no transfusion between first dose of study drug and the last dose of study drug + 30 days. The rate of conversion for red blood cells (RBC) and platelets is defined as percentage of participants being post-baseline transfusion independent from baseline transfusion dependence.

    Time frame: Measured up to 2 years after the last participant is randomized

  6. Complete Remission (CR) Rate

    The percentage of participants with complete remission (CR) will be calculated based on the modified IWG criteria for AML.

    Time frame: Measured up to 2 years after the last participant is randomized

  7. Fatigue/Quality of Life (QoL)

    Fatigue QoL will be assessed using the Patient Reported Outcomes Measurement Information System (PROMIS) Cancer Fatigue Short Form (SF) 7a global fatigue score

    Time frame: Measured at participant's Day 1 of Cycle 1 (each cycle is 28 days) and at Day 1 of every Cycle thereafter for up to 2 years following the last participant last visit

07

Results

Posted Jan 27, 2023

Participant flow

Participants were randomized in Group 1 per original protocol stratified by age (18 - \< 75, ≥ 75), and region (US, EU, Japan (JP), Rest of world (ROW)) and Group 2 during or after Amendment 1 stratified by age (18 - \< 75, ≥ 75), cytogenetic risk (intermediate, poor) and region (US, EU, China, JP, ROW).

Participant flow — Overall Study
MilestoneGroup 1: Placebo + Azacitidine 75 mg/m^2Group 1: Venetoclax 100 mg/200 mg/400 mg + Azacitidine 75 mg/m^2Group 2: Placebo + Azacitidine 75 mg/m^2Group 2: Venetoclax 100 mg/200 mg/400 mg + Azacitidine 75 mg/m^2Open Label China Cohort: Venetoclax 400 mg + Azacitidine 75 mg/m^2
Started1114528610
Completed001484
Not completed111442386
Withdrew: Withdrew consent00290
Withdrew: Lost to follow-up00360
Withdrew: Death111382226
Withdrew: Reason not specified00110

Outcome measures

PrimaryOverall Survival (OS)

OS is defined as the number of days from the date of randomization to the date of death. Log rank test was used to compare the OS distribution between two treatment arms. Cox regression was used to report the hazard ratio.

Time frame:
From the study start up to death or alive or lost to follow-up (up to approximately 4.8 years; data cut off date: 1 December 2021)
Reported as:
Median · months
Overall Survival (OS)
monthsGroup 2: Placebo + Azacitidine 75 mg/m^2Group 2: Venetoclax 100 mg/200 mg/400 mg + Azacitidine 75 mg/m^2
Overall Survival (OS)9.6 (7.4 to 12.7)14.7 (12.1 to 18.7)
Statistical analysis
  • Group 2: Placebo + Azacitidine 75 mg/m^2 vs Group 2: Venetoclax 100 mg/200 mg/400 mg + Azacitidine 75 mg/m^2 · Log Rank · p = <0.001 (Stratified log-rank test stratified by age (18 - \< 75, ≥ 75) and cytogenetic risk (intermediate, poor).) · Hazard ratio (hr): 0.580 · 95% CI 0.465 to 0.723HR from Cox proportional hazards model stratified by age (18 - \< 75, ≥ 75) and cytogenetic risk (intermediate, poor).
PrimaryPercentage of Participants With Complete Remission (CR) and Complete Remission With Incomplete Marrow Recovery (CRi)

CR and CRi was calculated based on current International Working Group (IWG) criteria. CR is defined as absolute neutrophil count \>10\^3/ microliter (mcL), platelets \>10\^5/mcL, red cell transfusion independence, and bone marrow with \<5% blasts. CRi is defined as bone marrow with less than 5% blasts, and absolute neutrophils of ≤10\^3/mcL or platelets ≤10\^5/mcL. Percentages are rounded off to whole number at the nearest decimal.

Time frame:
From the study start up to death (up to approximately 4.8 years; data cut-off date: 1 December 2021)
Reported as:
Number · percentage of participants
Percentage of Participants With Complete Remission (CR) and Complete Remission With Incomplete Marrow Recovery (CRi)
percentage of participantsGroup 2: Placebo + Azacitidine 75 mg/m^2Group 2: Venetoclax 100 mg/200 mg/400 mg + Azacitidine 75 mg/m^2Open Label China Cohort: Venetoclax 400 mg + Azacitidine 75 mg/m^2
CR17.9 (12.1 to 25.2)38.8 (33.1 to 44.7)60.0 (26.2 to 87.8)
CRi11.0 (6.4 to 17.3)28.0 (22.8 to 33.6)20.0 (2.5 to 55.6)
Statistical analysis
  • Group 2: Placebo + Azacitidine 75 mg/m^2 vs Group 2: Venetoclax 100 mg/200 mg/400 mg + Azacitidine 75 mg/m^2 · Cochran-Mantel-Haenszel · p = <0.001Cochran-Mantel-Haenszel (CMH) test stratified by age (18 - \< 75, ≥ 75) and cytogenetic risk (intermediate, poor).
SecondaryEvent-free Survival (EFS)

EFS will be defined as the number of days from randomization to the date of progressive disease, relapse from CR or CRi, treatment failure or death from any cause.

Time frame:
Measured up to 2 years after the last participant is randomized

Results for this outcome have not been posted.

SecondaryGlobal Health Status/Quality of Life (GHS/QoL)

Improvement in GHS/QoL will be assessed using the Patient Reported Outcomes Measurement Information System (PROMIS) and European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core (EORTC QLQ-C30).

Time frame:
Measured at participant's Day 1 of Cycle 1 (each cycle is 28 days) and at Day 1 of every Cycle thereafter for up to 2 years following the last subject last visit

Results for this outcome have not been posted.

SecondaryPercentage of Participants Achieving Composite Complete Remission (CR or CRi)

This will be calculated based on current International Working Group (IWG) criteria. CR is defined as absolute neutrophil count \> 10\^3/mcL, platelets \> 10\^5/mcL, red cell transfusion independence, and bone marrow with \< 5% blasts. CRi is defined as bone marrow with less than 5% blasts, and absolute neutrophils of \<= 10\^3/mcL or platelets \<= 10\^5/mcL.

Time frame:
Up to 6 months after the first 225 participants are randomized

Results for this outcome have not been posted.

SecondaryComplete Remission or Complete Remission With Partial Hematologic Recovery Rate (CR+CRh)

A response of CRh is defined as Bone marrow with \<5% blasts, peripheral blood neutrophil count \>0.5\*10\^3/mcL and peripheral blood platelet count \>0.5\*10\^5/mcL.

Time frame:
Measured up to 2 years after the last participant is randomized

Results for this outcome have not been posted.

SecondaryPost Baseline Transfusion Independence Rate

Transfusion Independence is defined as a period of 56 days with no transfusion between first dose of study drug and the last dose of study drug + 30 days. The rate of conversion for red blood cells (RBC) and platelets is defined as percentage of participants being post-baseline transfusion independent from baseline transfusion dependence.

Time frame:
Measured up to 2 years after the last participant is randomized

Results for this outcome have not been posted.

SecondaryComplete Remission (CR) Rate

The percentage of participants with complete remission (CR) will be calculated based on the modified IWG criteria for AML.

Time frame:
Measured up to 2 years after the last participant is randomized

Results for this outcome have not been posted.

SecondaryFatigue/Quality of Life (QoL)

Fatigue QoL will be assessed using the Patient Reported Outcomes Measurement Information System (PROMIS) Cancer Fatigue Short Form (SF) 7a global fatigue score

Time frame:
Measured at participant's Day 1 of Cycle 1 (each cycle is 28 days) and at Day 1 of every Cycle thereafter for up to 2 years following the last participant last visit

Results for this outcome have not been posted.

Adverse events

Collected over From the study start until data cut-off date: 01 December 2021 (up to approximately 4.8 years). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Group 1 and Group 2: Placebo + Azacitidine 75 mg/m^2140/144 (97.2%)111/144 (77.1%)137/144 (95.1%)
Group 1 and Group 2: Venetoclax 100 mg/200 mg/400 mg + Azacitidine 75 mg/m^2226/283 (79.9%)242/283 (85.5%)279/283 (98.6%)
Open Label China Cohort: Venetoclax 400 mg + Azacitidine 75 mg/m^26/10 (60%)7/10 (70%)10/10 (100%)
Most frequent serious events
Showing 10 of 341
Most frequent serious events
EventGroup 1 and Group 2: Placebo + Azacitidine 75 mg/m^2Group 1 and Group 2: Venetoclax 100 mg/200 mg/400 mg + Azacitidine 75 mg/m^2Open Label China Cohort: Venetoclax 400 mg + Azacitidine 75 mg/m^2
FEBRILE NEUTROPENIABlood and lymphatic system disorders15/14488/2832/10
NEUTROPENIABlood and lymphatic system disorders4/14414/2833/10
THROMBOCYTOPENIABlood and lymphatic system disorders3/14414/2833/10
PNEUMONIAInfections and infestations35/14455/2830/10
LUNG INFECTIONInfections and infestations3/14410/2832/10
CARDIAC FAILURECardiac disorders3/1447/2831/10
VERTIGOEar and labyrinth disorders0/1441/2831/10
PANCREATITIS ACUTEGastrointestinal disorders0/1440/2831/10
PSEUDOMONAL SEPSISInfections and infestations2/1442/2831/10
HYPOXIARespiratory, thoracic and mediastinal disorders1/1440/2831/10
Most frequent other events
Showing 10 of 120
Most frequent other events
EventGroup 1 and Group 2: Placebo + Azacitidine 75 mg/m^2Group 1 and Group 2: Venetoclax 100 mg/200 mg/400 mg + Azacitidine 75 mg/m^2Open Label China Cohort: Venetoclax 400 mg + Azacitidine 75 mg/m^2
LEUKOPENIABlood and lymphatic system disorders20/14454/28310/10
HYPOKALAEMIAMetabolism and nutrition disorders43/14484/2838/10
CONSTIPATIONGastrointestinal disorders55/144121/2837/10
ANAEMIABlood and lymphatic system disorders24/14468/2836/10
THROMBOCYTOPENIABlood and lymphatic system disorders57/144120/2836/10
DECREASED APPETITEMetabolism and nutrition disorders26/14478/2836/10
NEUTROPENIABlood and lymphatic system disorders38/144107/2835/10
DIARRHOEAGastrointestinal disorders46/144122/2835/10
VOMITINGGastrointestinal disorders33/14484/2835/10
HYPOCALCAEMIAMetabolism and nutrition disorders9/14419/2835/10

Baseline characteristics

Full Analysis Set included all Group 1 and 2 participants randomized by Interactive Voice Response System (IVRS)/Interactive Web Response System (IWRS) (exclude the open-label China safety cohort). Open-Label China Safety Cohort included participants who received at least one dose of venetoclax.

Age, Continuous
Age, Continuous(years)Group 1: Placebo + Azacitidine 75 mg/m^2Group 1: Venetoclax 100 mg/200 mg/400 mg + Azacitidine 75 mg/m^2Group 2: Placebo + Azacitidine 75 mg/m^2Group 2: Venetoclax 100 mg/200 mg/400 mg + Azacitidine 75 mg/m^2Open Label China Cohort: Venetoclax 400 mg + Azacitidine 75 mg/m^2Total
Mean61.0 ± NA65.0 ± NA75.1 ± 5.7075.6 ± 6.0870.2 ± 7.4475.2 ± 6.08
Sex: Female, Male
Sex: Female, Male(Participants)Group 1: Placebo + Azacitidine 75 mg/m^2Group 1: Venetoclax 100 mg/200 mg/400 mg + Azacitidine 75 mg/m^2Group 2: Placebo + Azacitidine 75 mg/m^2Group 2: Venetoclax 100 mg/200 mg/400 mg + Azacitidine 75 mg/m^2Open Label China Cohort: Venetoclax 400 mg + Azacitidine 75 mg/m^2Total
Female10581144177
Male01871726266
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Group 1: Placebo + Azacitidine 75 mg/m^2Group 1: Venetoclax 100 mg/200 mg/400 mg + Azacitidine 75 mg/m^2Group 2: Placebo + Azacitidine 75 mg/m^2Group 2: Venetoclax 100 mg/200 mg/400 mg + Azacitidine 75 mg/m^2Open Label China Cohort: Venetoclax 400 mg + Azacitidine 75 mg/m^2Total
American Indian or Alaska Native001001
Asian00336610109
Native Hawaiian or Other Pacific Islander000000
Black or African American102306
White011092170327
More than one race000000
Unknown or Not Reported000000
08

Study locations

172 sites

Showing the first 100 of 172 sites across 29 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Venditti A, Hou JZ, Fenaux P, Jonas BA, Vrhovac R, Montesinos P, Garcia JS, Rizzieri D, Thirman MJ, Zhang M, Potluri J, Miller C, Dhalla M, Pullarkat V. Outcomes of patients treated with venetoclax plus azacitidine versus azacitidine alone stratified by advanced age and acute myeloid leukemia composite model. Leukemia. 2025 Nov;39(11):2697-2707. doi: 10.1038/s41375-025-02730-3. Epub 2025 Sep 5. PubMed 40913104 ↗
  • Dohner H, Pratz KW, DiNardo CD, Wei AH, Jonas BA, Pullarkat VA, Thirman MJ, Recher C, Schuh AC, Babu S, Li X, Ku G, Liu Z, Sun Y, Potluri J, Dail M, Chyla B, Pollyea DA. Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine. Blood. 2024 Nov 21;144(21):2211-2222. doi: 10.1182/blood.2024024944. PubMed 39133921 ↗
  • Pollyea DA, Pratz KW, Wei AH, Pullarkat V, Jonas BA, Recher C, Babu S, Schuh AC, Dail M, Sun Y, Potluri J, Chyla B, DiNardo CD. Outcomes in Patients with Poor-Risk Cytogenetics with or without TP53 Mutations Treated with Venetoclax and Azacitidine. Clin Cancer Res. 2022 Dec 15;28(24):5272-5279. doi: 10.1158/1078-0432.CCR-22-1183. PubMed 36007102 ↗
  • Badawi M, Chen X, Marroum P, Suleiman AA, Mensing S, Koenigsdorfer A, Schiele JT, Palenski T, Samineni D, Hoffman D, Menon R, Salem AH. Bioavailability Evaluation of Venetoclax Lower-Strength Tablets and Oral Powder Formulations to Establish Interchangeability with the 100 mg Tablet. Clin Drug Investig. 2022 Aug;42(8):657-668. doi: 10.1007/s40261-022-01172-4. Epub 2022 Jul 13. PubMed 35829925 ↗
  • Pratz KW, Chai X, Xie J, Yin L, Nie X, Montez M, Iantuono E, Downs L, Ma E. Cost-Effectiveness Analysis of Venetoclax in Combination with Azacitidine Versus Azacitidine Monotherapy in Patients with Acute Myeloid Leukemia Who are Ineligible for Intensive Chemotherapy: From a US Third Party Payer Perspective. Pharmacoeconomics. 2022 Aug;40(8):777-790. doi: 10.1007/s40273-022-01145-7. Epub 2022 Jun 13. PubMed 35696071 ↗
  • Konopleva M, Thirman MJ, Pratz KW, Garcia JS, Recher C, Pullarkat V, Kantarjian HM, DiNardo CD, Dail M, Duan Y, Chyla B, Potluri J, Miller CL, Wei AH. Impact of FLT3 Mutation on Outcomes after Venetoclax and Azacitidine for Patients with Treatment-Naive Acute Myeloid Leukemia. Clin Cancer Res. 2022 Jul 1;28(13):2744-2752. doi: 10.1158/1078-0432.CCR-21-3405. PubMed 35063965 ↗
  • Pollyea DA, DiNardo CD, Arellano ML, Pigneux A, Fiedler W, Konopleva M, Rizzieri DA, Smith BD, Shinagawa A, Lemoli RM, Dail M, Duan Y, Chyla B, Potluri J, Miller CL, Kantarjian HM. Impact of Venetoclax and Azacitidine in Treatment-Naive Patients with Acute Myeloid Leukemia and IDH1/2 Mutations. Clin Cancer Res. 2022 Jul 1;28(13):2753-2761. doi: 10.1158/1078-0432.CCR-21-3467. PubMed 35046058 ↗
  • Pratz KW, Jonas BA, Pullarkat V, Recher C, Schuh AC, Thirman MJ, Garcia JS, DiNardo CD, Vorobyev V, Fracchiolla NS, Yeh SP, Jang JH, Ozcan M, Yamamoto K, Illes A, Zhou Y, Dail M, Chyla B, Potluri J, Dohner H. Measurable Residual Disease Response and Prognosis in Treatment-Naive Acute Myeloid Leukemia With Venetoclax and Azacitidine. J Clin Oncol. 2022 Mar 10;40(8):855-865. doi: 10.1200/JCO.21.01546. Epub 2021 Dec 15. PubMed 34910556 ↗
  • DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, Konopleva M, Dohner H, Letai A, Fenaux P, Koller E, Havelange V, Leber B, Esteve J, Wang J, Pejsa V, Hajek R, Porkka K, Illes A, Lavie D, Lemoli RM, Yamamoto K, Yoon SS, Jang JH, Yeh SP, Turgut M, Hong WJ, Zhou Y, Potluri J, Pratz KW. Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. N Engl J Med. 2020 Aug 13;383(7):617-629. doi: 10.1056/NEJMoa2012971. PubMed 32786187 ↗

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols, analyses plans, clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/

Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous independent scientific research, and will be provided following review and approval of a research proposal and statistical analysis plan and execution of a data sharing statement. Data requests can be submitted at any time after approval in the US and/or EU and a primary manuscript is accepted for publication. For more information on the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2017 to primary completion in Dec 2021, 57 months.

Results were first posted in Jan 2023, 1 year 1 month after primary completion.

Of 43 industry-sponsored phase 3 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 62. This study's 57 months is above that.

Counting every sponsor, half of 121 studies reached it within 74 months; a quarter within 39 and three quarters within 99.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 13, 2016
First posted
Dec 15, 2016
StartActual
Feb 2, 2017
Primary completionActual
Dec 1, 2021
CompletionEst.
Jun 15, 2026
Results first posted
Jan 27, 2023
Last update
Jun 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02993523
Lead sponsor
AbbVie
Collaborators
Genentech, Inc.
Responsible party
Sponsor
First posted
Dec 15, 2016
Start date
Feb 2, 2017
Primary completion
Dec 1, 2021
Completion
Jun 15, 2026 (estimated)
Results posted
Jan 27, 2023
Last update
Jun 11, 2026

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Venetoclax

Start the discussion